90 related articles for article (PubMed ID: 17604204)
1. The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy.
Wilson C; Spearing R; Teague L; Robertson P; Blacklock H
Mol Genet Metab; 2007; 92(1-2):131-6. PubMed ID: 17604204
[TBL] [Abstract][Full Text] [Related]
2. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
3. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
[TBL] [Abstract][Full Text] [Related]
6. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease.
Elstein D; Abrahamov A; Hadas-Halpern I; Meyer A; Zimran A
QJM; 1998 Jul; 91(7):483-8. PubMed ID: 9797931
[TBL] [Abstract][Full Text] [Related]
7. [Enzyme replacement therapy: a new treatment concept in Gaucher disease].
Beck M; Mengel E; Barone R
Wien Klin Wochenschr; 1997 Feb; 109(3):81-5. PubMed ID: 9139464
[TBL] [Abstract][Full Text] [Related]
8. A less costly regimen of alglucerase to treat Gaucher's disease.
Figueroa ML; Rosenbloom BE; Kay AC; Garver P; Thurston DW; Koziol JA; Gelbart T; Beutler E
N Engl J Med; 1992 Dec; 327(23):1632-6. PubMed ID: 1435900
[TBL] [Abstract][Full Text] [Related]
9. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.
Grabowski GA; Kacena K; Cole JA; Hollak CE; Zhang L; Yee J; Mistry PK; Zimran A; Charrow J; vom Dahl S
Genet Med; 2009 Feb; 11(2):92-100. PubMed ID: 19265748
[TBL] [Abstract][Full Text] [Related]
10. Gaucher's disease: a review.
Morales LE
Ann Pharmacother; 1996 Apr; 30(4):381-8. PubMed ID: 8729893
[TBL] [Abstract][Full Text] [Related]
11. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
12. Replacement therapy with imiglucerase for type 1 Gaucher's disease.
Zimran A; Elstein D; Levy-Lahad E; Zevin S; Hadas-Halpern I; Bar-Ziv Y; Foldes J; Schwartz AJ; Abrahamov A
Lancet; 1995 Jun; 345(8963):1479-80. PubMed ID: 7769903
[TBL] [Abstract][Full Text] [Related]
13. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
14. Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia.
Benedik-Dolničar M; Kitanovski L
Pediatr Int; 2011 Dec; 53(6):1018-22. PubMed ID: 21883686
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and therapy of Gaucher disease].
Ehlen C; Heintges T; Niederau C
Med Klin (Munich); 1995 May; 90(5):284-90. PubMed ID: 7791695
[TBL] [Abstract][Full Text] [Related]
17. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.
Whittington R; Goa KL
Pharmacoeconomics; 1995 Jan; 7(1):63-90. PubMed ID: 10155294
[TBL] [Abstract][Full Text] [Related]
18. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
19. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease.
Cohen IJ; Katz K; Kornreich L; Horev G; Frish A; Zaizov R
Blood Cells Mol Dis; 1998 Sep; 24(3):296-302. PubMed ID: 10087987
[TBL] [Abstract][Full Text] [Related]
20. Minimal disease activity in Gaucher disease: criteria for definition.
Di Rocco M; Andria G; Bembi B; Carubbi F; Giona F; Giuffrida G; Linari S; Sibilio M; Spina V; Cappellini MD
Mol Genet Metab; 2012 Nov; 107(3):521-5. PubMed ID: 22954583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
